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Rapid arterial rethrombosis is associated with high-grade
residual stenosis and usually occurs at the site of the initial
occlusion, resulting in reocclusion of the recanalized artery.
Platelets may play an active role in such rethrombosis after
thrombolytic-induced clot lysis. Given that glycoprotein
IIb/IIIa receptor blockers, like tirofiban, prevent thrombus
formation by inhibiting the final common pathway of platelet
aggregation, they may be helpful for treating rethrombosis
after thrombolysis. A 64-year-old man presented with an acute
ischemic stroke due to internal carotid artery (ICA) occlusion.
The ICA was recanalized by intravenous thrombolysis but
reoccluded shortly after recanalization. The reoccluded ICA
was successfully recanalized using intra-arterial tirofiban. A
carotid stent was subsequently inserted to relieve severe
stenosis and to prevent recurrent stroke. Here, we report a case
of rescue treatment of a successfully recanalized ICA by intra-
arterial tirofiban. We suggest that rescue use of intra-arterial
tirofiban may be effective and safe, especially in hemorrhage
prone situations, due to the relatively lower dose of tirofiban
compared with intravenous doses.
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INTRODUCTION
Reocclusion after successful arterial recanaliza-
tion occurs commonly in acute ischemic stroke.1,2
Rapid rethrombosis is associated with high-grade
residual stenosis and usually occurs at the site of
the initial occlusion, resulting in reocclusion of the
recanalized artery.3 Platelets may play an active
role in such rethrombosis following thrombolytic-
induced clot lysis.
Glycoprotein (GP) IIb/IIIa receptor blockers
prevent thrombus formation by inhibiting the
final common pathway of platelet aggregation.
There are three GP IIb/IIIa receptor blockers
(abciximab, tirofiban, eptifibatide) available for
clinical use. There are significant differences in the
biological and plasma half-lives of abciximab and
the small molecule agents (tirofiban and eptifi-
batide). Tirofiban is a small, non-peptide molecule
that has been used intravenously, in combination
with recombinant tissue plasminogen activator
(rt-PA), to treat patients with acute coronary
artery disease. Some promising pilot results using
intravenous tirofiban combined with throm-
bolytics for acute ischemic stroke have been
demonstrated.4,5
CASE REPORT
A 64-year-old man was admitted to the hospital
due to left-sided weakness and drowsiness. His
initial National Institutes of Health Stroke Scale
(NIHSS) score was 16. Brain CT showed no
low-density lesions, but bilateral cervical internal
carotid artery (ICA) occlusions were observed on
CT angiography (Fig. 1). Intravenous rt-PA was
administered 160 minutes after the initial onset of
symptoms. Because there was no improvement at
the end of the intravenous rt-PA infusion, we
proceeded to cerebral angiography to perform
intra-arterial thrombolysis. Cerebral angiography
showed complete occlusion of the left cervical ICA
and severe stenosis of the right cervical ICA (Fig.
2A) with delayed filling of the right middle
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cerebral artery and both anterior cerebral arteries.
The left ICA territory was supplied by an
ophthalmic collateral from the left external carotid
artery and pial collateral flow from the left
posterior cerebral artery. Due to the severe
stenosis of the right ICA and delayed intracranial
perfusion, plans were made to insert a carotid
stent to prevent recurrent ischemic stroke.
However, the right ICA was reoccluded approxi-
mately 20 minutes after the initial angiography
(Fig. 2B). Tirofiban was administered through the
microcatheter by hand injection. After injection of
200 g of tirofiban over five minutes, the occludedμ
ICA was recanalized with the remaining stenosis
as severe as that seen on initial angiography (Fig.
2C). We inserted a self-expandable carotid stent
(SMART, 7 × 80 mm Cordis, Warren, NJ, USA),
and subsequent angiography showed no rema-
ining stenosis (Fig. 2D). A brain MRI performed
10 days after thrombolysis showed acute cerebral
infarctions involving the right fronto-parietal and
medial frontal cortex. Four weeks following
thrombolysis, the patient's NIHSS score had
improved to six.
DISCUSSION
Fibrinolysis by rt-PA heightens platelet activity
and exposes clot-bound thrombin, facilitating
rethrombosis via the cleavage of fibrinogen to
fibrin.6 In addition, high blood flow velocity due
to remaining arterial stenosis may further activate
platelet aggregation. Thus, a blockade of platelet-
mediated thrombotic mechanisms appeared to be
a rational approach to the management of this
patient, as platelets seemed to play a key role in
the rethrombosis. Highly effective inhibition of
platelet activity can be achieved by the introduc-
tion of potent inhibitors of the GP IIb/IIIa
Fig. 1. Initial brain CT angiography shows bilateral
internal carotid artery occlusions.
Fig. 2. Serial cerebral angiography. (A) The initial angiography reveals severe stenosis of the right cervical ICA. (B)
Reocclusion of the right ICA 20 minutes after initial angiography. (C) After intra-arterial tirofiban infusion, the occluded
right ICA is recanalized and severe stenosis remains. (D) Final angiography after carotid stent insertion shows no stenosis
of the right ICA. ICA, internal carotid artery.
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receptor.
It has been reported that GP IIb/IIIa receptor
blockers can decrease the incidence of restenosis
and ischemic complications after percutaneous
transcoronary angioplasty.7 Recently, GP IIb/IIIa
receptor blockers were advocated as potentially
promising agents for acute stroke therapy, and
there were some case studies reporting the suc-
cessful rescue use of GP IIb/IIIa receptor blocker
in acute ischemic stroke.6,8-10 Tirofiban is a non-
peptide tyrosine derivative that mimics the RGD
integrin recognition sequence. It has a very short
platelet-bound half-life and a relatively long
plasma half-life, therefore providing an advantage
when the rapid reversal of antiplatelet action is
required such as in cases of high-risk hemorrhage
or in combined use with thrombolytics. It has
been reported that tirofiban produces a dose-de-
pendent, dethrombotic effect on thrombosis and
inhibits acute de novo stent thrombosis under
high-shear flow conditions in an ex vivo canine
arteriovenous shunt model.11 Tirofiban is generally
used intravenously in coronary artery disease,
with a loading dose of 0.4 g/kg/min for 30μ
minutes and a subsequent infusion of 0.1 g/kg/μ
min. We initially planned to use the standard
intravenous loading dose (900 g) intra-arterially;μ
however, after use of only 200 g intra-arterialμ
tirofiban, the ICA was successfully recanalized.
We speculate that intra-arterial drug delivery may
reduce the dose of tirofiban required to dissolve
the thrombus.
This case demonstrates that a GP IIb/IIIa
receptor blocker is effective for the recanalization
of reoccluded arteries, especially in the presence
of arterial stenosis. The dose of GP IIb/IIIa
receptor blocker can be reduced by intra-arterial
use, as compared with intravenous use and may
be effective at preventing hemorrhagic complica-
tions, especially when used in combination with
thrombolytics. Although this case showed pro-
mising results of intra-arterial tirofiban use,
further studies are necessary to verify the effect of
intra-arterial use of tirofiban and to determine its
proper dose.
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